Protagonist Therapeutics (PTGX) Change in Account Payables (2015 - 2026)

Protagonist Therapeutics has reported Change in Account Payables for 12 years, with the latest figure at $3.0 million in Q1 2026.

• Quarterly Change in Account Payables rose 142.76% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 million (up 835.79% YoY) and the FY2025 annual result came in at $3.7 million, up 342.16% from the prior year.
• Change in Account Payables advanced to $3.0 million in Q1 2026 per PTGX's latest filing, from -$307000.0 in the prior quarter.
• Over five years, Change in Account Payables peaked at $5.6 million in Q1 2022 and troughed at -$5.7 million in Q2 2022.
• A 5-year average of $227647.1 and a median of $37000.0 in 2022 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2023 and 2024: Change in Account Payables slumped 7672.97% in 2023, then jumped 6110.64% in 2024.
• Over 5 years, Change in Account Payables stood at $37000.0 in 2022, then plunged by 7672.97% to -$2.8 million in 2023, then jumped by 130.16% to $845000.0 in 2024, then slumped by 136.33% to -$307000.0 in 2025, then surged by 1078.18% to $3.0 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered $3.0 million, -$307000.0, and $2.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.